Business Wire

SPiCE VC Executes Third Investor Payout, Solidifying Position as Top Performing VC in Blockchain Sector

24.6.2025 16:00:00 EEST | Business Wire | Press release

Share

SPiCE VC, the leading venture capital fund focused on the blockchain and tokenization ecosystem, and the first fully tokenized VC fund pioneering Real World Asset (RWA) innovation, today announced its third investor payout—further cementing its position as both a category pioneer and one of the highest-performing funds in digital finance. With this latest distribution, scheduled for execution at the end of June, SPiCE’s total payouts to investors now exceed 2.1x DPI (Distributions to Paid-In Capital)—more than double what even top decile early-stage VC funds typically return by year seven.

By comparison, DPI for top-decile early-stage VC funds at the seven-year mark typically hovers around 1.0x, with most funds delivering significantly less. SPiCE’s latest performance far surpasses that benchmark, reflecting the strength of its portfolio and early strategic bets.

“We built SPiCE with a clear vision: to lead the blockchain investment frontier and deliver outsized value to our investors,” said Tal Elyashiv, Founder and Managing Partner of SPiCE VC. “Nearly doubling the average of our top-performing peers in all sectors is a testament to both our disciplined strategy and the long-term value we saw early in the Blockchain and digital finance revolution.”

Exceptional Returns in a Breakout Sector

SPiCE’s current TVPI (Total Value to Paid-In Capital) has now reached 6.3x, a performance metric rarely seen in early-stage VC. For context, top-decile funds in the same time frame typically report TVPIs between 3.0x and 4.5x, according to industry benchmarks from Cambridge Associates and PitchBook. SPiCE’s numbers place it in a league of its own—doubling top-tier results and far exceeding the market median of 1.3x–1.8x.

The fund’s portfolio includes standout performers like Securitize, Blockdaemon, and Ripio—companies that have become foundational players in the rapidly growing blockchain ecosystem space.

Pioneering Tokenization and Transparent Liquidity

After already completing two significant multi-million-dollar payouts in 2022—including the first-ever investor distribution by a fully tokenized VC fund—SPiCE is continuing to deliver unprecedented liquidity for its 400+ long-term investors. These milestone events showcase not only the strength of SPiCE’s portfolio, but also its innovative fund architecture that allows for earlier and more transparent returns.

Founded in 2018, SPiCE has built a diverse portfolio of 15 high-growth companies, each playing a critical role in the development of the blockchain and tokenization ecosystem. The firm was named the top performing fund in its category by Security Token Market, the leading media and data firm in the tokenized financial assets space.

Blockchain Investment with a Purpose

As one of the earliest VCs to specialize exclusively in blockchain ecosystem Originators and Disruptive Innovators, SPiCE attributes its success to a focused thesis: invest in the infrastructure and platforms powering the blockchain revolution. This strategy has helped the firm identify and back the most impactful players at the earliest stages, enabling it to outperform broader venture benchmarks while remaining a leader in a volatile, fast-moving sector.

“SPiCE is proving what’s possible when you combine a bold investment thesis with deep industry expertise and a commitment to transparency,” said Elyashiv. “We’re not just investing in blockchain—we’re building the ecosystem.”

About SPiCE VC

SPiCE VC is a Venture Capital fund providing investors exposure to the massive growth of the blockchain/tokenization ecosystem. SPiCE invests globally in platforms and ecosystem providers enabling access to capital markets, banking, real estate, and other industries enhanced through Blockchain technologies. The fund focuses on companies who stand to benefit the most from the massive growth of the industry. Combining institutional know-how, hands-on management, entrepreneurial innovation and professional investment experience SPiCE’s management team has been involved in hundreds of tech funding rounds totaling billions of dollars; as entrepreneurs, investors, and executives. SPiCE is located in the US, Singapore and Israel. To learn more about SPiCE VC visit www.spicevc.com or email Tal Elyashiv, Founder and Managing Partner, at tal@spicevc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250624244931/en/

Contacts

Liz Whelan
liz@lwprconsulting.com
(312) 315-0160

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye